AOD-9604 Dosage Guide: Protocols, Benefits & Side Effects (2026)

What Is AOD-9604? The HGH Fragment Explained

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically comprising amino acids 176–191. It was originally developed by Metabolic Pharmaceuticals Ltd as a potential pharmaceutical treatment for obesity, progressing through Phase II clinical trials before research interest shifted to the wellness and performance space.

Researchers discovered that this particular sequence of HGH is responsible for the hormone's lipolytic (fat-burning) activity — but critically, it does not carry HGH's growth-promoting or insulin-disrupting properties. This makes AOD-9604 a uniquely targeted metabolic tool. Unlike full-length HGH, it does not meaningfully raise IGF-1 levels, does not impair glucose regulation, and does not stimulate cellular proliferation.

Today, AOD-9604 is widely used as a research peptide in wellness clinics and by performance-focused individuals seeking fat loss without the hormonal risks of exogenous HGH.

Key Characteristics at a Glance

• Origin: Synthetic fragment of HGH (amino acids 176–191)
• Primary purpose: Fat loss, lipolysis stimulation, metabolic support
• IGF-1 impact: Minimal to none
• Insulin sensitivity: Does not negatively affect glucose regulation
• Administration: Subcutaneous injection (most common); oral and intranasal forms exist
• Research status: Investigational compound — not FDA-approved for human use

How AOD-9604 Works: Mechanisms of Action

Understanding how AOD-9604 works helps explain why its dosage protocol differs from HGH and why it is considered a safer alternative for fat-loss applications.

Primary Mechanisms

• Stimulates lipolysis: AOD-9604 activates beta-3 adrenergic receptors in adipose tissue, triggering the breakdown of stored triglycerides into free fatty acids and glycerol. These free fatty acids can then be oxidized for energy.
• Inhibits lipogenesis: The peptide suppresses the enzyme pathways responsible for converting excess dietary energy into new fat deposits, reducing the rate of fat storage.
• Promotes fat oxidation: By increasing the availability of free fatty acids and encouraging mitochondrial uptake, AOD-9604 supports the body's preference for fat as a fuel source — particularly relevant during caloric restriction or fasted training.
• No IGF-1 or glucose disruption: Because the 176–191 sequence lacks the growth-signaling domain of HGH, AOD-9604 does not activate IGF-1 pathways or interfere with insulin sensitivity — a critical safety advantage over exogenous HGH use.

In clinical research, AOD-9604 demonstrated fat-reducing effects in obese animal models and showed a favorable safety profile in human Phase II trials, with no significant adverse effects on blood glucose, IGF-1 levels, or cardiovascular markers.

AOD-9604 Benefits: What the Research and Clinical Use Suggest

AOD-9604's benefits are primarily centered on fat metabolism and body composition, but emerging research and anecdotal clinical data suggest broader potential applications.

1. Targeted Fat Loss Without Hormonal Side Effects

The most documented benefit is accelerated fat breakdown, particularly in adipose-dense regions. Because AOD-9604 does not raise IGF-1 or alter insulin dynamics, it avoids the metabolic complications associated with HGH — including insulin resistance, fluid retention, and carpal tunnel syndrome. This makes it especially attractive for individuals who want fat loss support without systemic hormonal disruption.

2. Improved Body Composition

By promoting lipolysis and inhibiting lipogenesis simultaneously, AOD-9604 helps shift body composition toward a leaner state. When paired with resistance training and appropriate caloric management, users report reductions in body fat percentage with preservation of lean mass.

3. Metabolic Enhancement

AOD-9604 may support overall metabolic rate by encouraging fat oxidation as a primary energy substrate. This can be particularly beneficial during caloric restriction phases, where the body might otherwise catabolize muscle tissue for energy.

4. Joint and Cartilage Support (Emerging Research)

Beyond fat metabolism, early-stage research has investigated AOD-9604's potential role in cartilage regeneration and joint repair. Some clinical work explored its use in osteoarthritis, suggesting possible connective tissue benefits — a reason it is sometimes stacked with BPC-157 in recovery-focused protocols.

5. Safety Profile Relative to HGH

In Phase II clinical trials, AOD-9604 showed no meaningful negative impact on fasting blood glucose, HbA1c, IGF-1 levels, or lipid panels. This safety data distinguishes it from full-length HGH and makes it a more accessible research option for metabolic support.

AOD-9604 Dosage Guide: Standard Protocols by Goal

AOD-9604 dosing in research and clinical settings varies based on the administration route, individual body weight, and specific goals. Below are the most widely referenced protocols.

Dosage by Administration Route

• Subcutaneous Injection (most common): 300–500 mcg per day. Injected into abdominal or upper thigh subcutaneous fat, ideally in a fasted state to maximize lipolytic activity.
• Oral / Sublingual: 1,000–2,000 mcg per day. Bioavailability via oral administration is significantly lower than injection; higher doses are used to compensate. Some compounded oral forms exist, though efficacy data is limited compared to injectable.
• Intranasal: 200–300 mcg per day. Nasal administration has moderate bioavailability and is used in some clinic settings as a needle-free alternative.

Dosage by Goal

• General fat loss / body composition: 300 mcg/day subcutaneous, taken fasted in the morning
• Aggressive fat loss / cutting phase: 500 mcg/day subcutaneous, timed 30 minutes before fasted cardio
• Joint and recovery support: 300 mcg/day combined with BPC-157 protocol
• Weight maintenance / metabolic support: 150–250 mcg/day as a lower-dose maintenance protocol

Timing Recommendations

AOD-9604 is most effective when administered in a fasted metabolic state. Insulin blunts fat-burning signals, so injecting AOD-9604 after eating — particularly after carbohydrates — reduces its lipolytic efficacy. Best practice is to inject upon waking (prior to breakfast) or 30–45 minutes before fasted exercise.

AOD-9604 Cycle Lengths and Protocols

Cycle length for AOD-9604 depends on the user's goals, tolerance, and whether it is being used as a standalone peptide or as part of a broader stack. Here are the most commonly recommended structures:

AOD-9604 Stacking: Best Combinations for Fat Loss and Recovery

AOD-9604 is frequently combined with other peptides to amplify fat loss, improve recovery, or target multiple metabolic pathways simultaneously. Here are the most evidence-informed stacks used in research and clinical settings.

Stack 1: AOD-9604 + CJC-1295 + Ipamorelin (Fat Loss + GH Optimization)

This is the most popular fat-loss peptide stack. CJC-1295 and Ipamorelin work synergistically to stimulate natural growth hormone pulses, which supports lean mass preservation and fat oxidation. AOD-9604 adds a direct lipolytic action on adipose tissue. Together, this triple stack addresses fat loss from multiple angles without exogenous HGH.

• AOD-9604: 300 mcg/day (morning, fasted)
• CJC-1295 (no DAC): 100 mcg before bed
• Ipamorelin: 100 mcg before bed (co-administered with CJC)

Stack 2: AOD-9604 + BPC-157 (Fat Loss + Recovery)

For individuals focused on body recomposition alongside injury recovery or joint health, combining AOD-9604 with BPC-157 provides complementary benefits. BPC-157 supports tendon, ligament, and gut tissue repair, while AOD-9604 drives fat metabolism. This is particularly useful during high-intensity training phases where recovery demand is elevated.

• AOD-9604: 300 mcg/day (morning, fasted)
• BPC-157: 250–500 mcg/day (near injury site or systemic)

Stack 3: AOD-9604 + Semaglutide (Aggressive Weight Management)

Some clinical protocols pair AOD-9604 with GLP-1 agonists like Semaglutide for individuals managing significant excess body weight. Semaglutide suppresses appetite and slows gastric emptying, while AOD-9604 drives direct lipolysis. This combination targets weight loss through appetite regulation and fat breakdown simultaneously. This stack should only be considered under medical supervision.

Stack 4: AOD-9604 + Sermorelin (GH Secretagogue Synergy)

For individuals prioritizing hormonal optimization alongside fat loss, stacking AOD-9604 with Sermorelin can support natural GH production while AOD-9604 directly drives fat breakdown. This is a gentler stack compared to CJC-1295/Ipamorelin and is often used in older adults with age-related GH decline.

AOD-9604 Side Effects: What to Expect and Watch For

AOD-9604 has a notably favorable safety profile compared to full-length HGH, as confirmed in Phase II clinical trials. However, as with any research peptide, side effects are possible and should be understood before starting a protocol.

Commonly Reported Side Effects

• Injection site reactions: Mild redness, swelling, or irritation at the subcutaneous injection site is the most frequently reported issue. Usually resolves within hours. Rotating injection sites minimizes this.
• Fatigue or lethargy: Some users report mild fatigue, particularly in the first 1–2 weeks. This typically subsides as the body adjusts.
• Headache: Mild headaches have been noted in some research participants, though they are generally transient.
• Nausea: Occasional nausea, typically associated with higher doses or administration without adequate hydration.

Side Effects NOT Typically Associated with AOD-9604

Unlike HGH, AOD-9604 does not commonly cause:

• Insulin resistance or blood sugar dysregulation
• Fluid retention or edema
• Carpal tunnel syndrome
• Elevated IGF-1 (and associated cancer risk concerns)
• Acromegaly (bone/organ growth) with prolonged use

Important Safety Considerations

• AOD-9604 has not been studied in pregnant or breastfeeding individuals — avoid use in these populations.
• Individuals with active malignancies should avoid any peptide therapy without oncologist consultation.
• Always source AOD-9604 from vendors providing third-party Certificate of Analysis (COA) — impure peptides carry significant contamination risks.
• Blood work before and after a cycle is strongly recommended, including fasting glucose, HbA1c, IGF-1, and a lipid panel.

AOD-9604 Legal Status: Is It Legal to Buy?

AOD-9604 occupies a complex regulatory position that varies by country. Understanding the legal landscape is essential before purchasing or using this compound.

• United States: AOD-9604 is not FDA-approved for human use or as a dietary supplement. It is classified as a research chemical and may be legally purchased for research purposes only. It is not permitted in compounded medications following recent FDA guidance on peptide compounding restrictions.
• Australia: AOD-9604 received TGA (Therapeutic Goods Administration) scheduling as a prescription-required substance. It has been available through some Australian compounding pharmacies but regulatory access has tightened in recent years.
• United Kingdom / EU: Not approved as a medicine. Classified as a research compound; personal importation laws vary by member state.
• Canada: Not approved by Health Canada. Treated similarly to the US framework — legal to purchase for research purposes, not for human consumption or commercial sale as a therapeutic.

Always verify the current regulatory status in your jurisdiction before purchasing. Laws around research peptides are evolving rapidly, particularly in the US and EU.

Frequently Asked Questions About AOD-9604

Where to Buy AOD-9604: What to Look For

If you are sourcing AOD-9604 for research purposes, vendor quality is critical. Peptide purity directly impacts both efficacy and safety. Here is what to verify before purchasing:

• Third-party Certificate of Analysis (COA): Must confirm ≥98% purity via HPLC and identity via mass spectrometry
• US-based lab or GMP-compliant manufacturing: Reduces risk of contaminated or mislabeled product
• Transparent sourcing: Vendor should be able to identify their manufacturing lab and testing facility
• Lyophilized powder form: Most stable for storage and shipping; avoid pre-mixed solutions of unknown stability
• Clear labeling: Product should display mcg per vial, batch number, and expiration

For a verified source with publicly available COAs and third-party testing, Ascension Peptides is among the most consistently recommended vendors in the research peptide community.